Clinical Trial Update: A Study of the Safety of R256918 in Obese Patients [Phase 2]

View source ↗

Summary

A Phase 2 safety study of R256918 in obese patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• R256918

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Obesity, Nutritional and Metabolic Diseases | Phase 2 | Status: COMPLETED